Dynamics of HBV cccDNA expression and transcription in different cell growth phase
© Chong et al; licensee BioMed Central Ltd. 2011
Received: 18 November 2011
Accepted: 30 December 2011
Published: 30 December 2011
The covalently closed-circular DNA (cccDNA) of hepatitis B virus (HBV) is associated with viral persistence in HBV-infected hepatocytes. However, the regulation of cccDNA and its transcription in the host cells at different growth stages is not well understood.
We took advantages of a stably HBV-producing cell line, 1.3ES2, and examine the dynamic changes of HBV cccDNA, viral transcripts, and viral replication intermediates in different cellular growth stages.
In this study, we showed that cccDNA increased suddenly in the initial proliferation phase of cell growth, probably attributable to its nuclear replenishment by intracellular nucleocapsids. The amount of cccDNA then decreased dramatically in the cells during their exponential proliferation similar to the loss of extrachromosomal plasmid DNA during cell division, after which it accumulated gradually while the host cells grew to confluency. We found that cccDNA was reduced in dividing cells and could be removed when proliferating cells were subjected to long term of lamivudine (3TC) treatment. The amounts of viral replicative intermediates were rapidly reduced in these proliferating cells and were significantly increased after cells reaching confluency. The expression levels of viral transcripts were increased in parallel with the elevated expression of hepatic transcription factors (HNF4α, CEBPα, PPARα, etc.) during cell growth confluency. The HBV transcripts were transcribed from both integrated viral genome and cccDNA, however the transcriptional abilities of cccDNA was less efficient then that from integrated viral genome in all cell growth stages. We also noted increases in the accumulation of intracellular viral particles and the secretion of mature virions as the cells reached confluency and ceased to grow.
Based on the dynamics of HBV replication, we propose that HBV replication is modulated differently in the different stages of cell growth, and can be divided into three phases (initial proliferation phase, exponential proliferation phase and growth confluency phase) according to the cell growth curve. The regulation of cccDNA in different cell growth phase and its importance regarding HBV replication are discussed.
KeywordsHBV cccDNA viral replication cell proliferation growth confluency
Infection with hepatitis B virus (HBV), which can cause acute and chronic liver diseases, remains one of the most serious viral infections in humans. Approximately 400 million people worldwide suffer from chronic hepatitis B (CHB) infection, and many of them have a high risk of developing cirrhosis or hepatocellular carcinoma [1, 2]. In CHB patients, a pool of covalently closed circular DNA (cccDNA), generated from the relaxed-circle (RC) form of viral DNA, is maintained in the nuclei of infected hepatocytes and acts as the template for viral gene expression . Within infected cells, the pregenomic RNA (pgRNA) is transcribed from cccDNA and reverse transcribed into RC form of viral DNA in the viral capsids . The mature capsids either are secreted from the cells or re-enter the nucleus to replenish the cccDNA pool [5, 6].
In addition to its crucial role in HBV life cycle, the existence of cccDNA interferes with the outcomes of clinical antiviral therapy. For example, lamivudine (3TC), an antiviral nucleoside analogue which inhibit viral polymerase activity, effectively inhibits HBV replication and eliminate the HBV virion from the blood of patients. However, the cessation of drug treatment results in the rapid reappearance of HBV in the serum [7, 8]. In vitro studies have shown that the persistence of cccDNA is responsible for the recurrence of HBV infection . Several studies have demonstrated that cccDNA is a very stable molecule. After treatment with antiviral drugs, the half-life of cccDNA was reported to range from 33 to 57 days in these hepadnaviruese-infected woodchucks and ducks [10, 11]. Traces of cccDNA persisted indefinitely in the livers of HBV-infected chimpanzees and provided a continuous antigenic stimulus that conferred lifelong immunity . Therefore, the elimination of cccDNA from infected cells, to achieve viral clearance, has become a major issue in the treatment of chronic HBV infection.
The regulatory mechanisms involved in the clearances of cccDNA pool are critical, but not well understood, processes during curing of chronic and acute HBV infection. It was generally believed that the clearance of cccDNA is mediated by the cellular immune response against HBV infection, which acts by: (a) the noncytopathic inhibitory effect of cytokines, which reduce the RC DNA precursors of cccDNA [13, 14]; (b) the cytopathic effect of the cytotoxic T-lymphocyte (CTL) response, which destroys the infected hepatocytes; and (c) the dilution effect achieved with the compensatory proliferation of the hepatocytes (mitotic loss) , which partitions the cccDNA during cell division [15, 16]. Among these, the antiviral effects of cytokines and CTL have been extensively investigated. However, the dilution effect and its relationship with the dynamics of cccDNA pool as well as HBV replication have not been examined closely.
Several lines of evidence have suggested that HBV replication is highly dependent on the growth status of hepatocytes. Clinical specimens show low levels of intrahepatic or serum-associated HBV during severe acute hepatitis at the time of active liver regeneration and inflammation, which represents a stage of rapid cell growth . Whereas, high levels of intrahepatic HBV replication are observed in immunosuppressed patients or neonates with normal or near-normal hepatic histology, in which the hepatocytes remain in the quiescent stage . Cell-cycle analysis has shown a correlation between elevated HBV replication and quiescent hepatocytes [17, 19]. Similar phenomena have also been observed in an HBV-transfected hepatoblastoma-derived cell line, which showed increased viral production during the cell growth confluency [4, 20]. Moreover, HBV replication and viral mRNA synthesis are significantly reduced in the proliferative stage [21, 22].
In this study, we took advantages of a stably HBV-producing cell line, 1.3ES2, to determine the dynamic changes of HBV cccDNA, viral transcripts, and viral replication intermediates in different cellular growth stages. Based on the status of cell proliferation, we purpose a three-phase scenario (initial proliferation phase, exponential proliferation phase, and growth confluency phase) to describe the dynamic expression of viral cccDNA and its association with HBV replication. Furthermore, our findings also raise the possibility that facilitating hepatocyte regeneration may interfere with cccDNA metabolism and contribute to viral elimination.
The 1.3ES2 cell line is derived from HepG2 cells (a differentiated hepatoblastoma cell line) and contains one integrated copy of the HBV genome . In this study, the cells were propagated in Dulbecco's modified Eagle's medium (DMEM) (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, and 100 μM non-essential amino acid. The cells were grown at 37°C in a 5% CO2 incubator. In each experiment, the culture medium was changed every three days. Lamivudine (3TC) was added to a final concentration of 20 μM for the experiment in which 3TC was used as an inhibitor of HBV replication. A hemocytometer was used for microscopic cell counts. The cell samples collected at each time points were appropriately diluted with GKNP (0.1% glucose, 0.04% KCl, 0.8% NaCl, 0.006% KH2PO4, 0.01% phenol red, pH 7.4) containing Trypan Blue. All counts were made in triplicate.
Hirt extraction of cccDNA and Southern blot analysis
To isolate cccDNA from 1.3ES2 cells, we used a previously described procedure, with modifications . The cells with equal cell number were washed twice with ice-cold GKNP, and the residual washing solution was then removed as completely as possible. The cells were lysed by the addition of 3 ml of Hirt solution (0.6% SDS, 10 mM EDTA, 10 mM Tris-HCl, pH 7.5) for 5 min. After complete lysis of the cells, 750 μl of 5 M NaCl was added to the cell lysate and mixed gently. After the whole mixture had been incubated on ice overnight, the insoluble components were pelleted by centrifuging at 3, 000 × g for 15 min at 4°C. The supernatant, which contained the cccDNA, was extracted twice with phenol and once with phenol-chloroform, and then precipitated with the addition of two volumes of absolute ethanol. The precipitates prepared from equal amount of cells were dissolved with water and then heated at 85°C for 5 min to denature the DNA. After EcoRI or XhoI digestion, these DNA samples were loaded into agarose gel and separated by electrophoresis. The agarose gel was soaked twice in denaturing buffer (0.5 M NaOH, 1.5 M NaCl) for 15 min each and then neutralized with neutralizing buffer (1.5 M NaCl, 10 M Tris-HCl, pH 8.0). The DNA samples were then transferred to nylon membranes Hybond-XL; (Amersham Pharmacia Biotech, NJ, USA) and UV cross-linked in a Stratalinker 2400 (Stratagene). The HBV-specific probe was prepared with the Rediprime™ II Random Prime Labelling System (Amersham). The membranes were prehybridized at 65°C for 4 h in HYB-9 DNA hybridization solution (Gentra) and then hybridized with the 32P-radiolabeled DNA probe (2 × 108 cpm/μL). After hybridization for 16 h, the membranes were washed three times (20 min each) with 0.2 × SSC/0.1% SDS at 52°C and then exposed to X-ray film for 16 h at -80°C.
Protein isolation and Western blot analysis
The cells were harvested for protein isolation in lysis buffer containing 1% Triton X-100 and the protease inhibitor Complete (Roche, Mannheim, Germany). The cell lysate was then centrifuged at 15, 500 × g for 15 min at 4°C, and the supernatant was collected. Total protein (100 μg) was separated by SDS-15% polyacrylamide gel electrophoresis (PAGE) and transferred onto PVDF membranes (Millipore Corp., Billerica, MA) using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad). The membranes were then blocked with 5% nonfat milk and probed with anti-HBc antibody (Dako Cytomation, Glostrup, Denmark) or anti-actin antibody (Sigma, St. Louis, MO). The immunoblot signals were detected with enhanced chemiluminescence reagent (PerkinElmer Life Sciences, Melbourne, Australia).
HBV particle isolation for encapsidated viral genome analysis
The intracellular HBV core particles were analyzed as previously described [24, 25]. Briefly, equal amounts of cell lysates were separated on a 1.2% native agarose gel and transferred onto nylon membrane to detect the capsid-associated nucleic acids. The capsid-associated nucleic acids were released from the core particles in situ by treating the membranes with 0.2 N NaOH/1.5 M NaCl and neutralizing them with 0.2 N Tris-HCl/1.5 M NaCl. Finally, the membranes were hybridized with HBV-specific probe.
The cells were washed twice with cold GKNP. TRIzol Reagent (Invitrogen) was then added, and the samples were placed on ice for 10 min to lyse the cells. For each 1 ml of TRIzol Reagent, 200 μl of chloroform was added and mixed by votexing for 15 s to homogenize the samples. The samples were centrifuged at 12, 000 rpm at 4°C for 15 min. Following centrifugation, the aqueous phase was transferred to a fresh tube, and the RNA was precipitated by adding 600 μl of isopropanol. The RNA pellets were collected after centrifugation and then dissolved in diethyl-pyrocarbonate-treated water. The RNA samples were ready for Northern blot analysis or reverse transcription (RT)-PCR.
Northern blot analysis
Fifteen micrograms of total RNA were resolved electrophoretically on a 1.2% agarose gel with 2.2 M formaldehyde, followed by upward transfer to a nylon membrane overnight, and cross-linked under UV. In this experiment, the HBV-specific probe was prepared from the DNA fragment amplified by PCR using the primer pair HBV2338/F' and T20-Taq/HBV5. A hybridization probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also prepared as the internal control for normalization. Prehybridization and hybridization were then performed in HYB-9 DNA hybridization solution (Gentra). After prehybridization at 65°C for 4 h, the probe was added and hybridized for 12-6 h. The membrane was washed three times with 1 × SSC/0.1% SDS buffer at 52°C for 20-30 min each. The RNA was detected by autoradiography with exposure to X-ray film for 16 h at -80°C.
Southern blot analysis
Twenty micrograms of total DNA was digested with HindIII and separated on a 1.2% agarose gel. After electrophoresis, the agarose gel was soaked in denaturing buffer (0.5 M NaOH, 1.5 M NaCl) twice for 15 min each time and then neutralized with neutralizing buffer (10 M Tris-HCl [pH 8.0], 1.5 M NaCl). The DNA samples were then transferred to nylon membranes (Hybond-XL; Amersham Pharmacia Biotech) and UV cross-linked. The membranes were prehybridized at 42°C for 4 h in prehybridization solution and then hybridized in hybridization solution with a 32P-radiolabeled DNA probe (2 × 108 cpm/μl; prepared using random oligonucleotide priming of the whole HBV genome). After 16 h of hybridization, membranes were washed three times (20 min for each time) with 0.2× SSC and 0.1% SDS at 52°C and then exposed to X-ray film for 16 h at -80°C.
Cell cycle analysis
Cells were harvested by trypsinization at each time course. The collected cells were then washed with PBS followed by 70% ethanol treatment. Finally the cells were incubated with 100 μg/ml RNaseA and 40 μg/ml propidium iodide (PI) for 30 minutes just before analysis by FACS calibur. The software Modfit LT was used to determine the cell cycle distribution after data acquisition.
RT-PCR and restriction enzyme digestion
cDNA templates were generated by the reverse transcription of total mRNA with oligo(dT) 18-mer primer and SuperScript II reverse transcriptase (Invitrogen), and then amplified by PCR with the primer pair HBV2338/F' and T20-Taq/HBV5. The thermocycling parameters were 94°C for 1 min; five cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 30 s; 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and then a final extension at 72°C for 10 min. The PCR products were eluted from the agarose gel after electrophoresis and subjected to BclI/SspI double digestion. To determine the relative amounts of the RT-PCR products generated from the integrated genome or cccDNA, the restricted samples were separated again by electrophoresis on a 2% agarose gel.
Quantification of HBsAg and HBeAg
The HBsAg and HBeAg in the culture medium were measured with an enzyme-linked immunosorbent assay (ELISA) Kit purchased from General Biology Corp The amount of formazan dye formed correlated with the amount of HBsAg or HBeAg, which was determined quantitatively using a scanning multi-well spectrophotometer (ELISA reader) at an absorbance of 450 nm. By using standards of HBsAg and HBeAg with known concentrations, the amounts of the secreted HBsAg and HBeAg were estimated.
Quantification of the HBV genome
Viral DNA was extracted from the culture media with the High Pure Viral Nucleic Acid Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. A series of dilutions of known concentrations of HBV DNA was used as the control. The standard curve showed a good linear range when 102-107 copies of plasmid DNA were used as the templates. The oligonucleotide sequences of the PCR primers were: HBV forward 5'-CAGGTCTGTGCCAAGT-3' and HBV reverse 5'-TGCGGGATAGGACAAC-3'. The PCR products were amplified using the SYBR Green PCR Master Mix (Roche). The PCR cycling program consisted of an initial denaturing step at 95°C for 10 min, followed by 45 amplification cycles at 95°C for 12 s and 54°C for 20 s.
Quantitative real-time PCR
The Universal Probe Library was used to quantify the hepatocyte-specific markers and transcription factors. The relevant probes were selected from the Universal Probe Library Set (human), and the corresponding primers were combined with them. The primer pairs used in the experiment were: HLF-forward (5'-TTCATCCCTGATGACCTGAA-3'), HLF-reverse (5'-TGCCATGTTGTTCTTTCTGC-3'), and probe #61; PPARAα-forward (5'-GAAGCTGTCCTGGCTCAGAT-3'), PPARAα-reverse (5'-TCCCCGCAGATTCTACATT-3'), and probe #14; RXRα-forward (5'-ACATGCAGATGGACAAGACG-3'), RXRα-reverse (5'-GAGAGCCCCTTGGAGTCAG-3'), and probe #26; NR2F1-forward (5'-ATCGTGCTGTTCACGTCAGA-3'), NR2F1-reverse (5'-GCTCCTCACGTACTCCTCCA-3'), and probe #02; NFIL3-forward (5'-CTCCCCCACTACTGCAAGTC-3'), NFIL3-reverse (5'-ATCAGTTTCCGACGTTCTCG-3'), and probe #65; HNF3β-forward (5'-CGTTCCGGGTCTGAACTG-3'), HNF3β-reverse (5'-ACCGCTCCCAGCATACTTT-3'), and probe #68; HNF4α-forward (5'-AACCTGTTGCAGGAGATGCT-3'), HNF4α-reverse (5'-CGTTGGTTCCCATATGTTCC-3'), and probe #77; CEBPα-forward (5'-CAACACTTGTATCTGGCCTCTG-3'), CEBPα-reverse (5'-CGAGCAAAACCAAAACAAAAC-3'), and probe #03; HNF1α-forward (5'-TGAGTCCGGGCTTCACAC-3'), HNF1α-reverse (5'-GGCTGCTGGAGGACACTG-3'), and probe #42; Alb-forward (5'-ATGTTGCCAAGCTGCTGATA-3'), Alb-reverse (5'-CCTTCATCCCGAAGTTCATC-3'), and probe #27; G6P-forward (5'-GCTGCTCATTTTCCTCATCAA-3'), G6P-reverse (5'-TTCTGTAACAGCAATGCCTGA-3'), and probe #67; TAT-forward (5'-TGCTGAGCAGTCTGTCCACT-3'), TAT-reverse (5'-CTGCTCACAGAACTCCTGGAT-3'), and probe #67; and B2M-forward (5'-TTCTGGCCTGGAGGCTATC-3'), B2M-reverse (5'-TCAGGAAATTTGACTTTCCATTC-3'), and probe #42. The real-time PCR was performed using a Roche machine.
The albumin secreted into the medium was measured with a Human Albumin ELISA Quantitation Kit from Bethyl Laboratories. Briefly, the culture medium collected at each time point was stored at -20°C until analysis. The samples were incubated on an ELISA plate coated with the capture antibody, followed by incubation with horseradish-peroxidase-conjugated antibody. Finally, the amount of albumin was measured with a microtiter plate reader at a wavelength of 450 nm by detecting the peroxidase activity after the substrate (TMB) had been added and the reaction stopped with H2SO4.
Densitometric measurements of band intensities were made to quantify the proteins/nucleic acids with the AlphaEaseFC Imaging System software version 6.0.0 (Alpha Innotech Corp.). In all cases, the samples collected at the first time point were deemed to be 100%. All statistical analyses were performed with Student's t test.
Dynamics of HBV replication during cell proliferation and growth confluency
The dynamic changes of HBV transcripts, intracellular viral DNA and cccDNA expression profiles during cell proliferation and growth confluency
Examination of the HBV cccDNA half-life in the HBV-producing 1.3ES2 cell line
The evaluation of transcriptional efficiency of HBV cccDNA during cells growth from proliferation to confluency
Expression of transcription factors and differentiation markers in long-term cultures of stably HBV-producing cells
It has been suggested that the expression of these hepatic transcription factors coordinately regulates hepatocyte differentiation [27–30] and that cellular differentiation is usually preceded by cell growth arrest [19, 31–33]. Therefore, we analyzed the expression of hepatocyte-specific differentiation markers by quantitative RT-PCR and examined their correlation with cell growth phases. The expression of albumin, tyrosine aminotransferase (TAT), and glucose-6-phosphatase (G6P) was up-regulated when the cells became confluent (Figure 5C). The culture medium was collected to determine the cellular albumin secretion. Consistent with the elevated levels of albumin transcriptions, the amount of secreted albumin increased progressively during cell growth to confluence (Figure 5D).
Dynamics of HBV replication in three different cell growth phases
The correlation between cell cycle phases and cccDNA accumulation
There are two previous achieves on studying the relationship between cell cycle phases and cccDNA accumulation [34, 35]. By using different cell cycle blocker (Aphidicolin or n-Butyrate), both groups examined the expression level of cccDNA in the cells of G1 arrest, but their studies led to completely conflicting conclusions. The inconsistency might caused by their different model systems (HBV-produced HepG2 cell line vs. In Vitro infection of duck hepatocyte cultures), using different G1 blockers (Aphidicolin vs. n-Butyrate), or different experimental designs used by these two groups. Our results showed that the accumulation of cccDNA was parallel with G1 arrest when cells were grown to conflurence (Figure 1A, E, and 1I), which is consistent with the previous report done by Yeh CT et al. . They demonstrated that viral RC-DNA imported into nuclear at the G1 phase and cccDNA accumulated after prolonged treatment of Aphidicolin (a G1 blocker). Different from their strategy, we kept culturing 1.3ES2 cells for 12 days (cell growth confluence) before re-plating instead of synchronization of these cells by serum starvation. Thus, large amounts of RC-DNA accumulated by 12 days of culture would serve as the source of cccDNA, once cells begin their initial proliferation after re-plating. However, our results also showed that the increase of cccDNA pool in the initial proliferation stage was not correlated to its G1 phase. This conflicting result indicated that the accumulation of cccDNA is not simply laid on the cell cycle phase (such as G1 arrest) and other parameter might also involve in the modulation of cccDNA pool. For example, as observed in the initial proliferation stage, large amount of protein-free RC-DNA and slower cell dividing rate might contribute, at least in part, to its conversion of RC-DNA to cccDNA. Consequently, we observed that the increase of cccDNA was accompanied with the decrease of protein-free viral DNA (ssDNA) in this stage (from day 0 to day 3). Moreover, we found that the cccDNA pool was dramatically reduced in the exponential proliferation stage (from day 3 to day 9), which is consistent with the findings (by Yeh CT et al. ) that a rapidly growing cell culture possibly did not have a G1 phase long enough for supporting the conversion of RC-DNA to cccDNA.
The dynamic expression of HBV transcripts and its regulation in different cell growth phase
As mentioned before, both integrated HBV genome and cccDNA molecule are able to serve as origins of HBV transcripts . However, the integrated HBV genome and the dynamic changes in cccDNA amount could only partially explain the gradual elevation of viral transcripts during cell growth. For example, in the growth confluency phase, cccDNA progressively accumulated inside the nucleus, providing increased templates for the transcription of viral mRNA. Indeed, the proportion of transcripts from cccDNA perfectly matched the kinetics of cccDNA accumulation during cell growth (Figure 4B and 4D, right panels). Nevertheless, the amount of cccDNA is not the only parameter involved in the elevation of viral mRNA expression. Our study revealed that the elevation of hepatic transcription factors might also contribute to the activation of HBV transcription. In the initial proliferating cells, we observed that the relatively lower amount of hepatic transcription factors paralleled the inefficient synthesis of viral transcripts even with a large amount of cccDNA in this stage (Figure 2A, C and 5B, day 3). In contrast, the expression levels of several hepatic transcription factors were elevated in the growth confluency phase (Figure 5B). Among these, HNF4α, PPARα, C/EBPα, and HLF have been suggested to function as positive regulators of HBV replication. For example, HNF4α and RXRα/PPARα have been shown to support HBV pgRNA synthesis and viral biosynthesis in nonhepatic cells [26, 36]. C/EBPα, together with HBx, has been reported to enhance the HBV pregenomic promoter synergistically in hepatocytes . HLF also exerts a stimulatory effect on the HBV promoter and strongly stimulates the synthesis of pgRNA . Taken together, these elevated hepatic transcription factors might coordinate with the accumulated cccDNA and comprehensively enhance HBV transcription efficiency as the cells gradually ceased to grow (Figure 4C, right panel). In conclusion, our data suggest that the transcriptional regulation of HBV is tightly controlled by the dynamic changes in cccDNA and cellular transcription factors during cell growth. Moreover, our results also showed the coordinately enhanced differentiation of 1.3ES2 cells as cells were grown to confluence (Figure 5C-D). The differentiation status of the hepatocytes paralleled the elevation of several hepatocyte-enriched transcription factors, which might stimulate viral transcription and enhance HBV replication. These findings were coincident with previous reports which showed a positive correlation between cell differentiation status and viral replication [39, 40].
Kinetic expression of intracellular DNA in different cell growth phases
The high intensity of viral RC and DL DNA in the beginning of initial proliferation stage indicated that large amount of intracellular nucleocapsids was accumulated before cell re-plating. However, once these cells started to proliferate, the intensity of intracellular viral DNA was gradually decreased (Figure 2B, days 0-3). Similar phenomena were found by tracing the dynamic expression of protein-free viral DNA (ssDNA), the presumed precursor of cccDNA  (Figure 2C, days 0-3). Meanwhile, a dramatic increase of HBV cccDNA pool was observed (Figure 2C, days 0-3), which suggested that the intracellular nucleocapsids were replenished into the nucleus and the embedded viral DNAs were converted to cccDNA in this stage. Coincident with the significant increase of HBV transcripts, the intracellular nucleocapsids (as revealed by the signals of RC and DL DNA) were dramatically elevated when these cells were grown to confluence (Figure 2B, days 9-24).
Dynamic expression of cccDNA in different cell growth phases
As mentioned above, the sudden increase of cccDNA was accompanied with a reduction of intracellular nucleocapsids when the host cells underwent their initial proliferation (Figure 2B-C, days 0-3). It seems that the disappearance of the nuclear membrane during mitosis facilitated the entry of pre-existing intracellular nucleocapsids into the nucleus, and the released protein-free RC DNA was consequently converted to cccDNA in the initial proliferation stage. However, once cells entered the exponential phase, the amount of cccDNA was declined dramatically (Figure 2C, days 4-8). Because the cccDNA lacks a replication origin, the reduction of cccDNA in the rapidly proliferating cells might be caused by a dilution effect similar to the loss of extrachromosomal plasmid DNA during cell division [42, 43]. After the cells reached confluence and ceased to grow, the intracellular nucleocapsids and protein-free viral DNA (ssDNA) accumulated markedly (Figure 2B-C, days 9-24), which could account for the gradual replenishment of cccDNA in the growth confluency phase. This observation is consistent with the previous report in which the HBV cccDNA formation in cultured cells is accompanied by the accumulation of protein-free viral DNA species .
The evaluation of viral transcriptional efficiency during cells growth to confluence
To evaluate the transcriptional efficiency of cccDNA in different cell growth phase, we carried out the RT-PCR combined with the restriction enzyme digestion assay . We found that the transcriptional ability of cccDNA was less efficient then that from integrated viral genome in all cell growth stages (Figure 4C, left panel). By comparing the relative intensities of PCR fragment from cccDNA (332-bp) and these from integrated viral genome (200-bp and 132-bp), the estimated proportion of transcripts from cccDNA relative to the amount from the integrated HBV genome was only 5% to 20% (Figure 4D and data not shown). However, the detail mechanism how transcription regulators manipulate the differential transcription efficiencies of cccDNA and integrated viral genome is not clarified yet. In spite of the lower amount of transcripts from cccDNA, the elevating potency of transcription from cccDNA was significantly raised during cell growth as compared with that from integrated viral genome (Figure 4C, right panel). To clarify precisely the proportions of transcripts from these two origins during cells growth to confluence, equal amounts of RT-PCR products were used to examine their transcriptional origins (Figure 4D). Interestingly, the proportional change of transcripts from cccDNA (Figure 4D, right panel) completely paralleled with the dynamic expression of cccDNA during cell growth (Figure 4B, right panel). In the meanwhile the proportion of transcripts from integrated genome remained constant (Figure 4D, right panel). It indicates that the higher elevation potency of transcription by cccDNA was resulted from the increase of cccDNA pool within the cells when cells were grown to confluence.
Modulation of cccDNA metabolism by cell proliferation
The amount of cccDNA was estimated to be approximately 4-6 copies of HBV cccDNA per cell on day 3 . During exponential proliferation, the cccDNA decreased rapidly to less than 0.4-0.6 copies per cell. Thereafter, the number of cccDNA copies per cell accumulated continuously during cell growth to confluence (Figure 4B). The constant presence of cccDNA in the hepatocyte is generally considered to play critical roles in the HBV life cycle, including in viral replication, persistent infection, and recurrence. cccDNA also functions as a risk marker for the development of hepatocellular carcinoma because hepatocarcinoma tissue is reported to have higher levels of cccDNA than non-tumor tissues . Therefore, the eradication of cccDNA from infected hepatocytes is considered to be the therapeutic goal for viral clearance in CHB patients. With lamivudine (3TC) treatment, we blocked the formation of newly synthesized cccDNA and determined the half-life of cccDNA in both proliferating cells and growth confluent cells (Figure 3). We found that the cccDNA molecule is extremely stable in the confluent cells, which still retained a constant amount of cccDNA after prolonged treatment with 3TC for 30 days (Figure 3D). This observed longevity of cccDNA is consistent with previous reports that cccDNA is a very stable molecule [10, 11]. Surprisingly, we found that cccDNA was dramatically reduced in the proliferating cells (Figure 3B). Without replenishment of cccDNA, the pre-existing cccDNA pool was dramatically diluted by rapid cell division. Moreover, the trace of cccDNA became undetectable by treating proliferating cells with 3TC for 9 days (Figure 3B). It suggests that the half-life of cccDNA is reduced and that the molecule is relatively unstable in proliferating cells. Several lines of evidence confirm our finding that cell division efficiently dilutes the amount of cccDNA in infected hepatocytes. For instance, in congenitally DHBV-infected hepatocyte cultures, the half-life of the DHBV cccDNA was estimated to be only 3-5 days in continuously proliferating cells, which confirms the loss of cccDNA during cell division . Similarly, a kinetic study of WHV loss after treatment with an antiviral agent suggested that the reduction in cccDNA might have been caused by its redistribution to the daughter cells of the infected hepatocytes . Moreover, an in vitro proliferation study of HBV-infected hepatocytes showed that cell division plays a crucial role in cccDNA clearance in the chronically infected hepatocytes . Because the elimination of cccDNA is essential for HBV clearance, our study provides the notion that the combination of treatment with an antiviral agent and the induction of cell proliferation, such as limited inflammation or partial hepatectomy, might accelerate cccDNA metabolism and facilitate viral clearance.
In this study, the dynamic changes of HBV cccDNA, viral transcripts, and viral replication intermediates in different cell growth stages were well investigated. Our study elucidated how the growth status of hepatocytes affects the formation of cccDNA. A three-phase scenario (initial proliferation phase, exponential proliferation phase, and growth confluency phase) describing the dynamic expression of viral cccDNA and its association with HBV replication was proposed. Moreover, we found that the half-life of cccDNA is reduced in dividing cells treated with lamivudine (3TC), and the cccDNA molecule could be completely removed by long-term treatment of 3TC. The significance of our findings regarding HBV regulation in CHB patients was discussed.
List of abbreviations
covalently closed-circular DNA
hepatitis B virus
chronic hepatitis B
This work was supported by an Intramural research grand PA-098-PP-08 from the National Health Research Institutes (NHRI), Taiwan (ROC).
- Kao JH, Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis. 2002, 2: 395-403.View ArticlePubMed
- Dienstag JL: Hepatitis B virus infection. N Engl J Med. 2008, 359: 1486-1500.View ArticlePubMed
- Tuttleman JS, Pourcel C, Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986, 47: 451-460.View ArticlePubMed
- Sells MA, Zelent AZ, Shvartsman M, Acs G: Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol. 1988, 62: 2836-2844.PubMed CentralPubMed
- Seeger C, Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000, 64: 51-68.PubMed CentralView ArticlePubMed
- Wu TT, Coates L, Aldrich CE, Summers J, Mason WS: In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 1990, 175: 255-261.View ArticlePubMed
- Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995, 333: 1657-1661.View ArticlePubMed
- Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H: Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 1996, 93: 4398-4402.PubMed CentralView ArticlePubMed
- Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC: Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol. 2002, 76: 8148-8160.PubMed CentralView ArticlePubMed
- Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS: Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001, 75: 311-322.PubMed CentralView ArticlePubMed
- Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, Tyrrell DL: Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol. 2002, 76: 6356-6363.PubMed CentralView ArticlePubMed
- Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV: Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA. 2004, 101: 2129-2134.PubMed CentralView ArticlePubMed
- Chou YC, Chen ML, Hu CP, Chen YL, Chong CL, Tsai YL, Liu TL, Jeng KS, Chang C: Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology. 2007, 46: 672-681.View ArticlePubMed
- Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, Chen ML, Chang C: HBV replication is significantly reduced by IL-6. J Biomed Sci. 2009, 16: 41-PubMed CentralView ArticlePubMed
- Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M: Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009, 51: 581-592.View ArticlePubMed
- Lutgehetmann M, Volz T, Kopke A, Broja T, Tigges E, Lohse AW, Fuchs E, Murray JM, Petersen J, Dandri M: In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology. 52: 16-24.
- Lugassy C, Bernuau J, Thiers V, Krosgaard K, Degott C, Wantzin P, Schalm SW, Rueff B, Benhamou JP, Tiollais P: Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis. 1987, 155: 64-71.View ArticlePubMed
- Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, Chen PJ, Chen DS: Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology. 1992, 15: 770-776.View ArticlePubMed
- Gruppuso PA, Bienieki TC, Faris RA: The relationship between differentiation and proliferation in late gestation fetal rat hepatocytes. Pediatr Res. 1999, 46: 14-19.View ArticlePubMed
- Sureau C, Romet-Lemonne JL, Mullins JI, Essex M: Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell. 1986, 47: 37-47.View ArticlePubMed
- Huang YQ, Wang LW, Yan SN, Gong ZJ: Effects of cell cycle on telomerase activity and on hepatitis B virus replication in HepG2 2.2.15 cells. Hepatobiliary Pancreat Dis Int. 2004, 3: 543-547.PubMed
- Ozer A, Khaoustov VI, Mearns M, Lewis DE, Genta RM, Darlington GJ, Yoffe B: Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology. 1996, 110: 1519-1528.View ArticlePubMed
- Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL, Liu YC, Hu CP, Chang C: Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol. 2005, 79: 1813-1823.PubMed CentralView ArticlePubMed
- Calvert J, Summers J: Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation. J Virol. 1994, 68: 2084-2090.PubMed CentralPubMed
- Biermer M, Puro R, Schneider RJ: Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol. 2003, 77: 4033-4042.PubMed CentralView ArticlePubMed
- Moolla N, Kew M, Arbuthnot P: Regulatory elements of hepatitis B virus transcription. J Viral Hepat. 2002, 9: 323-331.View ArticlePubMed
- Schrem H, Klempnauer J, Borlak J: Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev. 2004, 56: 291-330.View ArticlePubMed
- Ishiyama T, Kano J, Minami Y, Iijima T, Morishita Y, Noguchi M: Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci. 2003, 94: 757-763.View ArticlePubMed
- Cereghini S: Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 1996, 10: 267-282.PubMed
- Schrem H, Klempnauer J, Borlak J: Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev. 2002, 54: 129-158.View ArticlePubMed
- Yoon JH, Lee HS, Kim TH, Woo GH, Kim CY: Augmentation of urea-synthetic capacity by inhibition of nitric oxide synthesis in butyrate-induced differentiated human hepatocytes. FEBS Lett. 2000, 474: 175-178.View ArticlePubMed
- Felsher DW, Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999, 4: 199-207.View ArticlePubMed
- de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003, 370: 737-749.PubMed CentralView ArticlePubMed
- Yeh CT, Chiu HT, Chu CM, Liaw YF: G1 phase dependent nuclear localization of relaxed-circular hepatitis B virus DNA and aphidicolin-induced accumulation of covalently closed circular DNA. J Med Virol. 1998, 55: 42-50.View ArticlePubMed
- Turin F, Borel C, Benchaib M, Kay A, Jamard C, Guguen-Guillouzo C, Trepo C, Hantz O: n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol. 1996, 70: 2691-2696.PubMed CentralPubMed
- Tang H, McLachlan A: Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA. 2001, 98: 1841-1846.PubMed CentralView ArticlePubMed
- Choi BH, Park GT, Rho HM: Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem. 1999, 274: 2858-2865.View ArticlePubMed
- Ishida H, Ueda K, Ohkawa K, Kanazawa Y, Hosui A, Nakanishi F, Mita E, Kasahara A, Sasaki Y, Hori M, Hayashi N: Identification of multiple transcription factors, HLF, FTF, and E4BP4, controlling hepatitis B virus enhancer II. J Virol. 2000, 74: 1241-1251.PubMed CentralView ArticlePubMed
- Galle PR, Schlicht HJ, Kuhn C, Schaller H: Replication of duck hepatitis B virus in primary duck hepatocytes and its dependence on the state of differentiation of the host cell. Hepatology. 1989, 10: 459-465.View ArticlePubMed
- Glebe D, Berting A, Broehl S, Naumann H, Schuster R, Fiedler N, Tolle TK, Nitsche S, Seifer M, Gerlich WH, Schaefer S: Optimised conditions for the production of hepatitis B virus from cell culture. Intervirology. 2001, 44: 370-378.View ArticlePubMed
- Gao W, Hu J: Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol. 2007, 81: 6164-6174.PubMed CentralView ArticlePubMed
- Ganusov VV, Brilkov AV: Estimating the instability parameters of plasmid-bearing cells. I. Chemostat culture. J Theor Biol. 2002, 219: 193-205.View ArticlePubMed
- Jang JH, Rives CB, Shea LD: Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection. Mol Ther. 2005, 12: 475-483.PubMed CentralView ArticlePubMed
- Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL: Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006, 45: 553-559.View ArticlePubMed
- Civitico GM, Locarnini SA: The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology. 1994, 203: 81-89.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.